| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | — | — |
| Cost of Revenue | $6.0M | — | — |
| R&D Expense | $195.0M | — | +7.1% |
| SG&A Expense | $44.0M | — | +51.7% |
| Operating Income | -$244.0M | — | -15.6% |
| Pre-tax Income | -$223.0M | — | -7.2% |
| Income Tax | $0 | — | — |
| Net Income | -$223.0M | — | -7.2% |
| EPS (Basic) | -$0.11 | — | +8.3% |
| EPS (Diluted) | -$0.11 | — | +8.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $273.0M | +23.5% | +60.6% |
| Current Assets | $1.27B | -3.4% | +6.6% |
| Total Assets | $2.19B | -6.7% | +5.5% |
| Current Liabilities | $134.0M | +20.7% | +7.2% |
| Total Liabilities | $221.0M | +8.9% | -22.7% |
| Stockholders' Equity | $1.96B |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$159.0M | — | -12.0% |
| Capital Expenditures | $25.0M | — | +212.5% |
| Investing Cash Flow | $209.0M | — | +1000.0% |
| Financing Cash Flow | $4.0M | — | -95.1% |
| Free Cash Flow | -$184.0M | — | -22.7% |
| +10.0% |